Neurocrine
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
CEOKyle W. Gano
CEOKyle W. Gano
Employees1,800
Employees1,800
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded1992
Founded1992
Employees1,800
Employees1,800
NBIX Key Statistics
Market cap13.07B
Market cap13.07B
Price-Earnings ratio45.47
Price-Earnings ratio45.47
Dividend yield—
Dividend yield—
Average volume753.92K
Average volume753.92K
High today$134.94
High today$134.94
Low today$131.12
Low today$131.12
Open price$134.94
Open price$134.94
Volume709.59K
Volume709.59K
52 Week high$157.98
52 Week high$157.98
52 Week low$84.23
52 Week low$84.23
NBIX News
Simply Wall St 13h
Is Neurocrine Biosciences, Inc.'s Recent Stock Performance Influenced By Its Fundamentals In Any Way?Neurocrine Biosciences' (NASDAQ:NBIX) stock is up by a considerable 32% over the past three months. Given that stock prices are usually aligned with a company's...
TipRanks 4d
Neurocrine presents one-year data from study of CrenessityNeurocrine (NBIX) Biosciences announced the presentation of new one-year data from the CAHtalyst Adult study of Crenessity showing that patients achieved lastin...
Analyst ratings
85%
of 27 ratingsBuy
85.2%
Hold
14.8%
Sell
0%
People also own
Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.